Labcorp rolls out FDA‑cleared pTau‑181 Alzheimer’s blood test to primary care nationwide

Primary-care access widens for Alzheimer’s biomarker testing

Labcorp is rolling out the Elecsys pTau-181 blood test into primary care settings nationwide, offering clinicians a simple in‑office blood draw for symptomatic patients aged 55 and older. Developed by Roche Diagnostics and cleared by the U.S. Food and Drug Administration in 2025, the assay is now available at physician offices and any of Labcorp’s more than 2,200 patient service centers as an alternative to brain imaging or lumbar puncture.

Labcorp brings FDA-cleared pTau-181 into primary care

The company says the Elecsys pTau-181 is the first and only FDA‑cleared blood test intended to aid initial Alzheimer’s assessment in primary care, and it is being positioned to help clinicians rule out Alzheimer’s pathology by identifying patients unlikely to have amyloid buildup. Labcorp highlights a 97.9% negative predictive value for the assay, enabling primary care teams to direct patients with negative results toward evaluation for other causes of cognitive decline and to refer those with positive results for confirmatory testing.

Labcorp frames the expansion as a practical response to workforce constraints and access barriers. With a national shortage of neurologists and roughly 7.2 million Americans living with Alzheimer’s disease, the company says wider availability of a validated blood biomarker can reduce unnecessary specialist referrals, speed diagnostic pathways and support earlier, more timely conversations about care. Dr. Brian Caveney, Labcorp’s chief medical and scientific officer, notes primary care clinicians are often the first contact for cognitive concerns and that bedside-accessible testing helps patients get answers sooner and guide next steps with greater confidence.

Broader clinical implications

Clinicians and health systems gain a low‑burden screening tool that integrates with existing primary care workflows, Labcorp says, which may lower costs and shorten time to diagnosis compared with imaging or cerebrospinal fluid testing. The company anticipates the test will be used as an initial triage step rather than a stand‑alone diagnostic, informing decisions about further biomarker testing, neuroimaging or specialist referral.

Company strategy and market positioning

By adding Elecsys pTau-181 to its testing menu, Labcorp positions itself as a leader in expanding access to blood‑based biomarkers for neurodegenerative disease evaluation. The move aligns with the company’s stated commitment to improve diagnostic access and provide clinicians actionable results that streamline care and inform treatment discussions.